SYN RSI Chart
Last 7 days
2.7%
Last 30 days
-13.6%
Last 90 days
-19.1%
Trailing 12 Months
-24.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2021 | 0 | 0 | 0 | 0 |
2011 | 0 | 0 | 0 | 0 |
2010 | 0 | 0 | 0 | 2.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 10, 2021 | shallcross steven a | bought | 24,595 | 0.4919 | 50,000 | ceo and cfo |
Aug 23, 2019 | shallcross steven a | bought | 20,785 | 0.4157 | 50,000 | ceo and cfo |
Apr 03, 2019 | kirk randal j | sold | -16,952 | 0.65 | -26,080 | - |
Apr 03, 2019 | kirk randal j | sold | -44,954 | 0.65 | -69,161 | - |
Apr 02, 2019 | kirk randal j | sold | -2,466 | 0.66 | -3,737 | - |
Apr 02, 2019 | kirk randal j | sold | -6,539 | 0.66 | -9,909 | - |
Apr 01, 2019 | kirk randal j | sold | -7,646 | 0.67 | -11,413 | - |
Apr 01, 2019 | kirk randal j | sold | -20,277 | 0.67 | -30,265 | - |
Which funds bought or sold SYN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -20,455 | - | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 1,894 | 22,836 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -97.09 | -215 | 7.00 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | - | 3.00 | -% |
May 15, 2024 | Steward Partners Investment Advisory, LLC | unchanged | - | 1.00 | 7.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | unchanged | - | 6.00 | 68.00 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 9,977 | 9,977 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | sold off | -100 | -12,270 | - | -% |
May 15, 2024 | Royal Bank of Canada | added | 28.57 | - | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -57.42 | -13,352 | 11,574 | -% |
Unveiling Synthetic Biologics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Synthetic Biologics Inc News
Income Statement (Quarterly) | |||||||
Description | (%) Q/Q | 2021Q1 | 2011Q3 | 2011Q2 | 2010Q4 | 2010Q3 | 2010Q2 |
Revenue | -100.0% | - | 293,421 | 355,562 | 322,730 | 289,898 | 2,194,888 |
Operating Expenses | - | 2,537,000 | - | - | - | - | - |
S&GA Expenses | - | 1,419,000 | - | - | - | - | - |
R&D Expenses | - | 1,118,000 | - | - | - | - | - |
EBITDA Margin | -Infinity% | -6.10 | - | - | - | - | - |
Earnings Before Taxes | 100.0% | - | -871,000 | -805,000 | - | - | - |
EBT Margin | -Infinity% | -6.17 | - | - | - | - | - |
Net Income | -Infinity% | -2,536,000 | - | - | - | - | - |
Net Income Margin | -Infinity% | -3.68 | - | - | - | - | - |
Free Cashflow | -Infinity% | -3,342,000 | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -11.8% | 49.00 | 55.00 | 62.00 | 65.00 | 68.00 | 72.00 | 77.00 | 81.00 | 89.00 | 70.00 | 75.00 | 77.00 | 79.00 | 8.00 | 7.00 | 10.00 | 12.00 | 17.00 | 21.00 | 24.00 | 27.00 |
Current Assets | -21.0% | 22.00 | 27.00 | 35.00 | 38.00 | 40.00 | 46.00 | 53.00 | 55.00 | 60.00 | 69.00 | 74.00 | 76.00 | 79.00 | 8.00 | 7.00 | 9.00 | 11.00 | 16.00 | 20.00 | 23.00 | 26.00 |
Cash Equivalents | -20.8% | 18.00 | 23.00 | 31.00 | 34.00 | 36.00 | 42.00 | 50.00 | 52.00 | 57.00 | 67.00 | 72.00 | 74.00 | 77.00 | 6.00 | 6.00 | 8.00 | 10.00 | 15.00 | 19.00 | 22.00 | 25.00 |
Net PPE | -11.1% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
Goodwill | -2.2% | 6.00 | 6.00 | 5.00 | 6.00 | 6.00 | 6.00 | 5.00 | 6.00 | 6.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | -5.9% | 15.00 | 16.00 | 18.00 | 18.00 | 17.00 | 17.00 | 18.00 | 18.00 | 21.00 | 5.00 | 5.00 | 4.00 | 2.00 | 3.00 | 3.00 | 4.00 | 3.00 | 6.00 | 6.00 | 4.00 | 4.00 |
Current Liabilities | -10.8% | 6.00 | 7.00 | 9.00 | 9.00 | 9.00 | 7.00 | 12.00 | 12.00 | 11.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 5.00 | 6.00 | 4.00 | 3.00 |
Shareholder's Equity | -15.1% | 31.00 | 37.00 | 41.00 | 45.00 | 48.00 | 52.00 | 56.00 | 62.00 | 68.00 | 65.00 | 71.00 | 74.00 | 77.00 | - | - | - | - | 2.00 | 2.00 | 7.00 | 11.00 |
Retained Earnings | -1.7% | -314 | -309 | -303 | -300 | -295 | -290 | -284 | -280 | -275 | -271 | -266 | -262 | -259 | -248 | -244 | -242 | -238 | -235 | -232 | -227 | -223 |
Additional Paid-In Capital | 0.0% | 347 | 347 | 346 | 346 | 344 | 344 | 344 | 344 | 343 | 337 | 339 | 339 | 339 | 241 | 236 | 235 | 234 | 233 | 232 | 232 | 232 |
Shares Outstanding | 0% | 17.00 | 17.00 | 17.00 | 17.00 | 15.00 | 15.00 | 16.00 | 16.00 | 14.00 | 13.00 | 12.00 | 13.00 | 9.00 | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | -2.77 | -2.77 | -2.77 | -2.77 | -2.75 | -2.88 | -2.88 | -2.88 | -2.84 | -2.85 | -2.87 |
Float | - | - | - | - | 16,791,123 | - | - | - | 33.00 | - | - | - | 79.00 | - | - | - | 8.00 | - | - | - | 9.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 25.4% | -4,881 | -6,541 | -2,953 | -3,892 | -5,610 | -5,368 | -4,456 | -4,356 | -4,902 | -4,810 | -2,156 | -2,596 | -3,328 | -3,132 | -2,050 | -2,026 | -4,960 | -3,605 | -3,062 | -2,982 | -4,224 |
Share Based Compensation | 10.3% | 160 | 145 | 135 | 146 | 126 | 129 | 121 | 113 | 112 | 111 | 102 | 102 | 101 | 99.00 | 82.00 | 86.00 | 83.00 | 94.00 | 91.00 | 91.00 | 64.00 |
Cashflow From Investing | 100.0% | - | -56.00 | -129 | -9.00 | -8.00 | -91.00 | -11.00 | -14.00 | -4,280 | - | - | - | -14.00 | -5.00 | -4.00 | - | - | - | - | - | - |
Cashflow From Financing | 100.0% | - | -1,457 | 1.00 | 2,136 | -55.00 | -3,288 | 2,734 | - | -1,376 | - | - | - | 74,002 | 3,359 | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating Costs and Expenses: | ||
General and administrative | $ 1,933 | $ 2,201 |
Research and development | 3,459 | 2,977 |
Total Operating Costs and Expenses | 5,392 | 5,178 |
Loss from Operations | (5,392) | (5,178) |
Other Income: | ||
Foreign currency exchange (loss) gain | (1) | 6 |
Interest income | 228 | 364 |
Total Other Income | 227 | 370 |
Net Loss before income taxes | (5,165) | (4,808) |
Income tax benefit | 330 | |
Net Loss Attributable to Common Stockholders | $ (5,165) | $ (4,478) |
Net Loss Per Share - Basic (in dollars per share) | $ (0.30) | $ (0.30) |
Net Loss Per Share - Dilutive (in dollars per share) | $ (0.30) | $ (0.30) |
Weighted average number of shares outstanding during the period - Basic (in shares) | 17,148,049 | 15,124,061 |
Weighted average number of shares outstanding during the period - dilutive (in shares) | 17,148,049 | 15,124,061 |
Net Loss | $ (5,165) | $ (4,478) |
(Loss) gain (loss) on foreign currency translation | (569) | 374 |
Total comprehensive loss | $ (5,734) | $ (4,104) |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 18,261,000 | $ 23,177,000 |
Tax credit receivable | 1,772,000 | 1,812,000 |
Prepaid expenses and other current assets | 1,623,000 | 2,414,000 |
Total Current Assets | 21,656,000 | 27,403,000 |
Non-Current Assets | ||
Property and equipment, net | 375,000 | 422,000 |
Restricted cash | 99,000 | 102,000 |
Right of use asset | 1,634,000 | 1,759,000 |
In-process research and development | 19,316,000 | 19,755,000 |
Goodwill | 5,573,000 | 5,700,000 |
Deposits and other assets | 77,000 | 78,000 |
Total Assets | 48,730,000 | 55,219,000 |
Current Liabilities: | ||
Accounts payable | 571,000 | 770,000 |
Accrued expenses | 3,327,000 | 2,995,000 |
Accrued employee benefits | 665,000 | 1,517,000 |
Deferred research and development tax credit-current portion | 886,000 | 906,000 |
Loans payable-current | 62,000 | 63,000 |
Operating lease liability-current portion | 498,000 | 487,000 |
Total Current Liabilities | 6,009,000 | 6,738,000 |
Non-current Liabilities | ||
Non-current contingent consideration | 6,476,000 | 6,274,000 |
Loan Payable - non-current | 159,000 | 162,000 |
Non-current deferred research and development tax credit | 664,000 | 906,000 |
Non-current operating lease liability | 1,299,000 | 1,442,000 |
Total Liabilities | 14,607,000 | 15,522,000 |
Commitments and Contingencies (Note 13) | ||
Stockholders' Equity: | ||
Common stock, $0.001 par value; 350,000,000 shares authorized, 17,868,282 issued and 17,148,049 outstanding at March 31, 2024 and 17,868,282 issued and 17,148,049 outstanding at December 31, 2023 | 18,000 | 18,000 |
Additional paid-in capital | 346,679,000 | 346,519,000 |
Treasury stock at cost, 720,233 shares at March 31, 2024 and at December 31, 2023 | (288,000) | (288,000) |
Accumulated other comprehensive (loss) income | (537,000) | 32,000 |
Accumulated deficit | (314,483,000) | (309,318,000) |
Total Stockholders' Equity | 31,389,000 | 36,963,000 |
Total Liabilities and Stockholders' Equity | 48,730,000 | 55,219,000 |
Series C convertible preferred stock | ||
Temporary Equity | ||
Convertible preferred stock | 2,006,000 | 2,006,000 |
Series D convertible preferred stock | ||
Temporary Equity | ||
Convertible preferred stock | $ 728,000 | $ 728,000 |